Figure 2.

Long-term effects of pegvisomant (PEG) on cardiac parameters in patients with controlled acromegaly (IGF1 <115% ULN). Upper panels: individual values of IGF1 (A), left ventricular ejection fraction (LVEF) (B) and left ventricular mass index (LVMi) (C) in 29 patients before pegvisomant and at the first on-treatment evaluation. Middle panels: individual values of IGF1 (D, n=23), LVEF (E, n=16) and LVMi (F, n=19) before pegvisomant and at the first and second on-treatment evaluations. Lower panel: individual values of IGF1 (G), LVEF (H) and LVMi (I) in nine patients before pegvisomant and at the first, second and third on-treatment evaluations. Statistical significance: *P<0.05, **P<0.01, ***P<0.001.